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We live in a golden age for the development of innovative radiotherapy technologies. Three major new 
treatment platforms are currently at various stages of being implemented globally: stereotactic 
ablative radiotherapy (SABR)[1]; MR-guided radiotherapy (MR-Linac)[2]; and proton beam therapy 
(PBT)[3]. Such technologies offer huge opportunities for clinical benefit, but also present significant 
challenges for development, assessment and rational implementation within an increasingly financially 
constrained National Health Service (NHS). However, the apparent restrictions imposed by the 
structure of the NHS can also be viewed as a benefit for developing and proving the value of new 
radiotherapy technologies. In large part, this is due to the need to provide robust evidence to support 
the implementation of new technological developments before they can become widely available 
nationally.  For example, the recent development, assessment and widespread adoption of intensity-
modulated radiotherapy (IMRT) in the UK was driven by a programme of preclinical and clinical studies 
that were led initially by a small number of academic centres, but which progressively involved and 
finally included the majority of radiotherapy units in the UK[4-7]. A by-product of this research is that 
the UK has provided the international community with the best evidence-base for the use of IMRT in 
a variety of indications (e.g. prostate, breast and head and neck cancers). 
 
In a similar vein, there is a drive in the UK to, develop SABR, MR-Linac and PBT as part of a co-ordinated 
programme of research.  This programme can best be delivered through a co-operative network that 
brings together the leading radiotherapy research centres in the UK. Without such a structure, there 
is a real danger that new technologies will be introduced piecemeal with variable quality, in a spirit of 
competition rather than collaboration, being driven by market forces, rather than being based on their 
potential for achieving clinical benefit. For these reasons, we have established the Advanced 
Radiotherapy Technologies Network (ART-NET), based at The Institute of Cancer Research/Royal 
Marsden Hospital (ICR), Leeds, Manchester Cancer Research Centre (MCRC), Oxford, and University 





A key aim of ART-NET is to generate and disseminate national treatment protocols as a means of 
improving and harmonising practice. This will ultimately result in properly selected patients gaining 
access to and benefiting from these technologies. Such protocols will also facilitate the subsequent 
development of collaborative clinical trials in the UK aiming to generate a robust evidence-base on 
which practice change can be based. 
 
ART-NET is underpinned by the availability of an impressive array of state-of-the-art technologies 
across the participating centres: all 5 centres have the technological capability to deliver SABR; ICR and 
the MCRC are members of the global MR-Linac Consortium and have already installed their MR-Linacs; 
MCRC and UCL are developing proton beam facilities, the first patient to be treated in 2018 in 
Manchester. A critical aspect of the network is that, even in the absence of the specific hardware, each 
member will make significant contributions to the physics/planning developments that will be required 
to translate these technologies for clinical evaluation, because the modalities do have a lot in common, 
in particular regarding issues related to patient geometry changes. In addition, sharing of expertise in 
clinical trial methodology (ICR/Leeds) and health economics (MCRC/Oxford) will add significant value 
to the network. ART-NET will involve a multi-disciplinary group of researchers including clinical 
oncologists, medical physicists, research radiographers, methodologists and health economists.   
 
In establishing the network, each centre has signed a consortium agreement that was developed in 
consultation with collaborating centres and with CRUK. The agreement governs decision-making 
processes, management arrangements, funding, reporting and intellectual property. We have 
established a Steering Committee (SC) (Table 1) for the Network, comprised of representatives from 
all partner institutions and a representative from CRUK.  
 
ART-NET’s mission is to: 
 build a national co-operative group drawn from UK centres of excellence that will provide 
leadership for the development, assessment and clinical implementation of new 
radiotherapy technologies; 
 develop and disseminate the essential expertise in Medical Physics to lead the development 
of planning and image-guided solutions for SABR, MR-Linac and PBT; 
 co-ordinate crucial methodological developments in the design and conduct of clinical trials 
to streamline health technology assessments of new technologies in specific tumour types; 
 
 
 lead on health economic assessments that will estimate cost savings that will be achieved 
through these technologies and guide the scope of investment that will be necessary across 
the NHS; 
 conduct in silico modelling and prospective cohort studies of new technologies that will 
provide the rationale for subsequent response mode-funded randomised evaluations that 
will be disseminated across the UK; 
 disseminate national treatment protocols developed through this award to other UK centres; 
 train clinical researchers of the future in the field of advanced radiotherapy.  
 
ART-NET will initially focus on a number of disease sites including prostate, rectal, lung and 
oesophageal cancers and central nervous system, but will subsequently establish mechanisms for 
ongoing research on these technology platforms in a range of other tumour types. One central, 
unifying theme of the network is to evaluate the new technological platforms as a means of delivering 
hypofractionated radiotherapy in a range of clinical indications. In recent years, the orthodox view that 
curative radiotherapy must be administered in conventional fractions of around 2 Gy, in order to limit 
normal tissue toxicities, has been overturned[8,9]. As a result, there has been a drive towards testing 
hypofractionated regimens and, thus far, this has been particularly successful in lung, breast and 
prostate cancers[10-12]. Investigators at the ICR have led research in breast and prostate cancer that has 
shown that good tumour control rates can be maintained (or even improved) with equivalent levels of 
normal tissue damage when delivering a smaller number of larger doses of radiation. In addition to 
significant clinical benefits that will arise from increased use of hypofractionation, there are huge 
implications for the NHS, because  reducing the number of treatment fractions delivered is a large cost 
saving. These savings will, to some extent, be offset by additional costs of delivering advanced 
radiotherapy. Assessment of the balance between these competing effects will be a central 
component of ART-NET and will provide guidance for the implementation and dissemination of the 
advanced treatment platforms that we are assessing. 
 
Each platform each offer great opportunities to develop optimised hypofractionated radiation 
approaches, with both generic and platform-specific challenges that will need to be addressed and 
solved by the ART-NET investigators. Individual research workstreams (Table 2) will be based on 
providing the solutions to a number of key challenges for advanced radiotherapy technologies. The 
strength of the ART-NET approach is that, for each of these challenges, leadership will be provided by 
at least 2 of the network members, with the ability to draw on expertise from each of the other centres. 
Importantly, the structure that we establish will be based on sharing information across the network, 
 
 
but it will also facilitate education and skill transfer between centres and, eventually, beyond ART-NET 
to the wider UK radiotherapy community.  
 
Although the individual technologies each present their own specific challenges, we believe that there 
is considerable scope for lessons to be shared across the network in order to maximise research 
outputs and accelerate clinical translation. This collaborative framework will allow us to move away 
from the historical approach of single-centre early development and will significantly accelerate the 
process of translating each of the new technologies into the clinic. Specific workstreams will address 
problems relating to advanced treatment delivery, including MR-based planning (Workstream 1) and 
fast/adaptive treatment (re)planning and interactive dose-shaping (Workstream 2), management of 
organ motion (Workstream 3), the delivery of functional MR image-guided radiotherapy (Workstream 
4) and the development of effective image-guidance and dose verification for PBT (Workstream 5). In 
addition, health economics methodology will be employed to assess the cost effectiveness of new 
treatment approaches and this information will be used as a component of the overall health 
technology assessment to inform plans for implementation and dissemination across the UK 
(Workstream 6). Finally, specific activity will also include consideration of methodological aspects of 
evaluating new radiotherapy technologies and how to assess their clinical utility (Workstream 7). This 
is particularly important, given the fact that traditional phase III clinical trials may not be the most 
effective means of assessing some indications for these technologies.  
 
During the 5-year funding period, we will establish an enduring UK-wide culture of collaborative 
working. Initially, this will be based within the 5 founding centres of ART-NET and the selected 
radiotherapy technology platforms. However, by the time of the completion of the Network Award, 
we will have engaged large sections of the UK RT community in ART-NET and will have established a 
framework that will drive nationwide improvements in RT. By disseminating national protocols, ART-
NET will allow all centres in the UK to offer their patients state-of-the-art treatment, either in clinical 
trials or as standard-of-care. We anticipate that ART-NET will solve key problems relating to SABR, MR-
Linac and PBT, but will also define residual problems that will need to be addressed through further 
funding applications beyond the period of the Network Award. We expect to be able to attract ongoing 
grant funding from CRUK and non-CRUK sources (e.g. MRC, NIHR) and support from industrial partners. 
Furthermore, the clinical research fellows in ART-NET will help to develop a skilled workforce that will 
be a huge asset for future radiotherapy research in the UK. Finally, the enhanced network-wide 
working that we will have established will ensure that future studies will be rapid and streamlined, 
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Table 1: ART-NET Steering Committee Members  
 
Centre Committee member Deputies 
ICR/RM Kevin Harrington (Chair) Uwe Oelfke / Chris Nutting / Emma Hall  
Leeds David Sebag-Montefiore Ann Henry / Vivian Cosgrove 
MCRC Marcel van Herk Corinne Faivre-Finn / Ranald MacKay 
Oxford Maria Hawkins Frank Van den Heuvel / Tim Maughan / 
Alistair Gray  
UCL Gary Royle Dave Hawkes / Ricky Sharma 
 
ICR/RM – Institute of Cancer Research/Royal Marsden 
MCRC – Manchester Cancer Research Centre 

































Provide guidance on QA of MR and image registration software to implement MR 
in routine clinical practice for SABR. 
Standardise algorithms that generate synthetic CT images (syCTs) from treatment-
integrated MR images for all selected clinical treatment sites and the spectrum of 
applied imaging protocols. 
Implement image processing tools to allow verification of the geometrical 
accuracy of the acquired MR images by comparison with prior information. 
2 Fast/adaptive re-
planning 
Share tools to generate images suitable for dose calculations from online images 
(CBCT, MR). 
Implement fast segmentation tools across the network. 
Disseminate ultra-fast Monte-Carlo dose algorithms for photon and proton 
beams. 
Multi-site implementation of a high-performance inverse planning tool exploiting 
modern computational CPU and GPU hardware architectures. 
3 Motion 
management 
Image library-based (3-D, 4-D) quantification of organ motion and anatomical 
changes in tumour and adjacent critical structures. 
Evaluation of novel 4-D acquisition, reconstruction, and motion modelling 
approaches and determine their suitability for clinical use. 
Quantification of treatment platform-independent uncertainties (eg delineation 
variability and short term organ motion) and their effect on predictions of 
tumour/normal organs motion. 
Evaluation of the accuracy of image-guidance methodologies for each treatment 
platform. 
4 Functional imaging Development of MRI-based early predictors of radiotherapy response. 
Design of one prospective validation study to demonstrate that predictors of 
response have utility in a multi-site and multi-vendor trial. 
5 Proton image-
guidance and dose 
verification 
Protocol for correction of range differences at all PBT centres. 
In silico validation of protocol of determination of proton range using motion 
management system. 
Evaluate proton range verification techniques and identify margins for complex 
treatments. 
6 Health economics Development of health economic methodology. 
Comparative assessment of SABR, PBT and MR-Linac for prostate cancer. 
Comparative assessment of SABR, PBT and MR-Linac for second site (e.g. lung, 
oesophagus). 
7 Trial methodology Recommendations for development pathways for new RT technologies into 
practice-changing clinical trials.  Assess feasibility/delivery of PBT and MR-Linac 
clinical trials including assessment of logistics and equipoise. 
Development of core outcome set – treatment, dosimetry, safety, efficacy, 
effectiveness, including electronic platforms for patient-reported outcomes. 




3-D  3-Dimensional 
4-D  4-Dimensional 
CBCT  Cone Beam Computed Tomography 
CPU  Central Processing Unit 
CT  Computed Tomography 
GPU  Graphics Processing Unit 
MR  Magnetic Resonance 
MRI  Magnetic Resonance Imaging 
PBT  Proton Beam Therapy 
QA  Quality Assurance 
RT  Radiotherapy 
SABR  Stereotactic Ablative Radiotherapy 
TSG  Trial Steering Groups 
 
 
 
